Received Jul 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 3N2ND | — |
adult patient that inadvertently received the pediatric dose; adult patient that inadvertently received the pediatric dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 24-year-old male patient who received HBV (Engerix B pediatric) (batch number 3N2ND, expiry date 16-JAN-2027) for prophylaxis. On 16-JUL-2025, the patient received Engerix B pediatric. On 16-JUL-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: adult patient that inadvertently received the pediatric dose) and accidental underdose (Verbatim: adult patient that inadvertently received the pediatric dose). The outcome of the adult use of a child product and accidental underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-JUL-2025 Pharmacist wanted to know if she could give a second pediatric dose to complete a full dose of Engerix-B in an adult patient that inadvertently received the pediatric dose. Adult patient received pediatric of dose of Engerix B, which led to adult use of a child product and accidental underdose.